×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Update From the US FDA on Progress and Topics of Current Interest in US Biosimilar Policy, Regulation, and Outreach/Education
Session Chair(s)
Sarah Yim, MD
Director, Office of Therapeutic Biologics and Biosimilars, OND, CDER
FDA, United States
This session will include an update from members of the US FDA on progress and topics of current interest in US biosimilar policy, regulation, and outreach/education.
Learning Objective : Discuss topics of current interest in US biosimilar policy.
Speaker(s)
FDA Update
Joseph B. Franklin, JD, PhD
Verily, United States
Head of Strategic Affairs
FDA Update
Sarah Crowley-Ikenberry, MA
FDA, United States
Senior Communication Advisor, OTBB, OND, CDER
FDA Update
Christopher Downey, PhD
FDA, United States
Review Chief, OBP, OPQ, CDER
Have an account?